X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs STERLING BIOTECH - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD STERLING BIOTECH MERCK LTD/
STERLING BIOTECH
 
P/E (TTM) x 34.2 -1.6 - View Chart
P/BV x 3.8 0.1 6,005.9% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 MERCK LTD   STERLING BIOTECH
EQUITY SHARE DATA
    MERCK LTD
Dec-16
STERLING BIOTECH
Dec-13
MERCK LTD/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,06011 10,095.2%   
Low Rs6233 18,323.5%   
Sales per share (Unadj.) Rs632.426.8 2,359.2%  
Earnings per share (Unadj.) Rs45.7-15.0 -305.7%  
Cash flow per share (Unadj.) Rs62.3-5.5 -1,140.7%  
Dividends per share (Unadj.) Rs11.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs388.854.9 708.5%  
Shares outstanding (eoy) m16.60267.87 6.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.30.3 513.2%   
Avg P/E ratio x18.4-0.5 -3,961.3%  
P/CF ratio (eoy) x13.5-1.3 -1,061.4%  
Price / Book Value ratio x2.20.1 1,709.0%  
Dividend payout %24.10-   
Avg Mkt Cap Rs m13,9691,862 750.3%   
No. of employees `0001.61.4 116.9%   
Total wages/salary Rs m1,487547 271.9%   
Avg. sales/employee Rs Th6,631.95,303.3 125.1%   
Avg. wages/employee Rs Th939.2403.8 232.6%   
Avg. net profit/employee Rs Th479.4-2,959.0 -16.2%   
INCOME DATA
Net Sales Rs m10,4987,181 146.2%  
Other income Rs m24243 569.0%   
Total revenues Rs m10,7417,223 148.7%   
Gross profit Rs m1,135947 119.9%  
Depreciation Rs m2762,543 10.8%   
Interest Rs m04,377 0.0%   
Profit before tax Rs m1,102-5,931 -18.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m343-1,924 -17.8%   
Profit after tax Rs m759-4,007 -18.9%  
Gross profit margin %10.813.2 82.0%  
Effective tax rate %31.132.4 96.0%   
Net profit margin %7.2-55.8 -13.0%  
BALANCE SHEET DATA
Current assets Rs m6,41014,335 44.7%   
Current liabilities Rs m8,82849,809 17.7%   
Net working cap to sales %-23.0-494.0 4.7%  
Current ratio x0.70.3 252.3%  
Inventory Days Days58403 14.3%  
Debtors Days Days38171 22.5%  
Net fixed assets Rs m1,40655,432 2.5%   
Share capital Rs m166268 62.0%   
"Free" reserves Rs m6,28613,935 45.1%   
Net worth Rs m6,45514,701 43.9%   
Long term debt Rs m09,478 0.0%   
Total assets Rs m8,82873,988 11.9%  
Interest coverage xNM-0.4-  
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.20.1 1,225.3%   
Return on assets %8.60.5 1,716.2%  
Return on equity %11.8-27.3 -43.1%  
Return on capital %17.1-6.4 -265.7%  
Exports to sales %8.325.9 32.0%   
Imports to sales %21.00.2 12,385.8%   
Exports (fob) Rs m8691,860 46.7%   
Imports (cif) Rs m2,20912 18,108.2%   
Fx inflow Rs m9591,860 51.6%   
Fx outflow Rs m2,61225 10,494.2%   
Net fx Rs m-1,6531,835 -90.1%   
CASH FLOW
From Operations Rs m1,0701,719 62.3%  
From Investments Rs m-750-3,148 23.8%  
From Financial Activity Rs m-1501,426 -10.5%  
Net Cashflow Rs m171-3 -5,026.5%  

Share Holding

Indian Promoters % 0.0 33.9 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 0.0 -  
FIIs % 1.0 9.9 10.1%  
ADR/GDR % 0.0 16.9 -  
Free float % 29.1 39.3 74.0%  
Shareholders   28,591 21,482 133.1%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  IPCA LABS  

Compare MERCK LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD 8-QTR ANALYSIS

COMPARE MERCK LTD WITH

MARKET STATS